Metastases of prostate cancer express estrogen receptor-beta

Janice S. Lai, Lisha G. Brown, Lawrence D. True, Sarah J. Hawley, Ruth Etzioni, Celestia S. Higano, Shuk Mei Ho, Robert L. Vessella, Eva Corey

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

To examine estrogen receptor-beta (ERβ) expression in prostate cancer (CaP) metastases, thereby providing a basis for conducting estrogen therapy studies in patients with metastatic CaP. Advanced androgen-independent CaP is a serious health problem with no effective treatment at present. Estrogens have been reported to inhibit the growth of CaP cells in androgen-free environments. Recent reports have shown that the prostatic epithelium and primary CaP cells express ERβ, with decreased expression of ERβ accompanying CaP progression. It has been proposed that ERβ may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP. The anti-ERβ antibody GC17 was used in immunohistochemistry to characterize the expression of ERβ in CaP metastasis specimens (n = 60) obtained from 20 patients who had died of CaP. Statistical analyses were performed to evaluate the association of ERβ expression with clinical parameters, including prostate-specific antigen levels, radiotherapy, and estrogen exposure. Nuclear ERβ staining was detected in all bone CaP metastases (33 of 33) and nonosseous CaP metastases (27 of 27). However, a large variability in the percentage of immunoreactive cells (5% to 100%) was found among patients, as well as among individual patient samples. A statistically significant negative association between nuclear ERβ staining and estrogen exposure (P = 0.05) was detected. Our data have shown that ERβ is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP.

Original languageEnglish (US)
Pages (from-to)814-820
Number of pages7
JournalUrology
Volume64
Issue number4
DOIs
StatePublished - Oct 1 2004
Externally publishedYes

Fingerprint

Estrogen Receptor beta
Prostatic Neoplasms
Neoplasm Metastasis
Estrogens
Selective Estrogen Receptor Modulators
Androgens
Staining and Labeling
Prostate-Specific Antigen
Growth
Prostate
Radiotherapy
Therapeutics
Epithelium

ASJC Scopus subject areas

  • Urology

Cite this

Lai, J. S., Brown, L. G., True, L. D., Hawley, S. J., Etzioni, R., Higano, C. S., ... Corey, E. (2004). Metastases of prostate cancer express estrogen receptor-beta. Urology, 64(4), 814-820. https://doi.org/10.1016/j.urology.2004.05.036

Metastases of prostate cancer express estrogen receptor-beta. / Lai, Janice S.; Brown, Lisha G.; True, Lawrence D.; Hawley, Sarah J.; Etzioni, Ruth; Higano, Celestia S.; Ho, Shuk Mei; Vessella, Robert L.; Corey, Eva.

In: Urology, Vol. 64, No. 4, 01.10.2004, p. 814-820.

Research output: Contribution to journalArticle

Lai, JS, Brown, LG, True, LD, Hawley, SJ, Etzioni, R, Higano, CS, Ho, SM, Vessella, RL & Corey, E 2004, 'Metastases of prostate cancer express estrogen receptor-beta', Urology, vol. 64, no. 4, pp. 814-820. https://doi.org/10.1016/j.urology.2004.05.036
Lai JS, Brown LG, True LD, Hawley SJ, Etzioni R, Higano CS et al. Metastases of prostate cancer express estrogen receptor-beta. Urology. 2004 Oct 1;64(4):814-820. https://doi.org/10.1016/j.urology.2004.05.036
Lai, Janice S. ; Brown, Lisha G. ; True, Lawrence D. ; Hawley, Sarah J. ; Etzioni, Ruth ; Higano, Celestia S. ; Ho, Shuk Mei ; Vessella, Robert L. ; Corey, Eva. / Metastases of prostate cancer express estrogen receptor-beta. In: Urology. 2004 ; Vol. 64, No. 4. pp. 814-820.
@article{d23c0cc5a34f4bf18cf953fb7f58224f,
title = "Metastases of prostate cancer express estrogen receptor-beta",
abstract = "To examine estrogen receptor-beta (ERβ) expression in prostate cancer (CaP) metastases, thereby providing a basis for conducting estrogen therapy studies in patients with metastatic CaP. Advanced androgen-independent CaP is a serious health problem with no effective treatment at present. Estrogens have been reported to inhibit the growth of CaP cells in androgen-free environments. Recent reports have shown that the prostatic epithelium and primary CaP cells express ERβ, with decreased expression of ERβ accompanying CaP progression. It has been proposed that ERβ may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP. The anti-ERβ antibody GC17 was used in immunohistochemistry to characterize the expression of ERβ in CaP metastasis specimens (n = 60) obtained from 20 patients who had died of CaP. Statistical analyses were performed to evaluate the association of ERβ expression with clinical parameters, including prostate-specific antigen levels, radiotherapy, and estrogen exposure. Nuclear ERβ staining was detected in all bone CaP metastases (33 of 33) and nonosseous CaP metastases (27 of 27). However, a large variability in the percentage of immunoreactive cells (5{\%} to 100{\%}) was found among patients, as well as among individual patient samples. A statistically significant negative association between nuclear ERβ staining and estrogen exposure (P = 0.05) was detected. Our data have shown that ERβ is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP.",
author = "Lai, {Janice S.} and Brown, {Lisha G.} and True, {Lawrence D.} and Hawley, {Sarah J.} and Ruth Etzioni and Higano, {Celestia S.} and Ho, {Shuk Mei} and Vessella, {Robert L.} and Eva Corey",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.urology.2004.05.036",
language = "English (US)",
volume = "64",
pages = "814--820",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Metastases of prostate cancer express estrogen receptor-beta

AU - Lai, Janice S.

AU - Brown, Lisha G.

AU - True, Lawrence D.

AU - Hawley, Sarah J.

AU - Etzioni, Ruth

AU - Higano, Celestia S.

AU - Ho, Shuk Mei

AU - Vessella, Robert L.

AU - Corey, Eva

PY - 2004/10/1

Y1 - 2004/10/1

N2 - To examine estrogen receptor-beta (ERβ) expression in prostate cancer (CaP) metastases, thereby providing a basis for conducting estrogen therapy studies in patients with metastatic CaP. Advanced androgen-independent CaP is a serious health problem with no effective treatment at present. Estrogens have been reported to inhibit the growth of CaP cells in androgen-free environments. Recent reports have shown that the prostatic epithelium and primary CaP cells express ERβ, with decreased expression of ERβ accompanying CaP progression. It has been proposed that ERβ may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP. The anti-ERβ antibody GC17 was used in immunohistochemistry to characterize the expression of ERβ in CaP metastasis specimens (n = 60) obtained from 20 patients who had died of CaP. Statistical analyses were performed to evaluate the association of ERβ expression with clinical parameters, including prostate-specific antigen levels, radiotherapy, and estrogen exposure. Nuclear ERβ staining was detected in all bone CaP metastases (33 of 33) and nonosseous CaP metastases (27 of 27). However, a large variability in the percentage of immunoreactive cells (5% to 100%) was found among patients, as well as among individual patient samples. A statistically significant negative association between nuclear ERβ staining and estrogen exposure (P = 0.05) was detected. Our data have shown that ERβ is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP.

AB - To examine estrogen receptor-beta (ERβ) expression in prostate cancer (CaP) metastases, thereby providing a basis for conducting estrogen therapy studies in patients with metastatic CaP. Advanced androgen-independent CaP is a serious health problem with no effective treatment at present. Estrogens have been reported to inhibit the growth of CaP cells in androgen-free environments. Recent reports have shown that the prostatic epithelium and primary CaP cells express ERβ, with decreased expression of ERβ accompanying CaP progression. It has been proposed that ERβ may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP. The anti-ERβ antibody GC17 was used in immunohistochemistry to characterize the expression of ERβ in CaP metastasis specimens (n = 60) obtained from 20 patients who had died of CaP. Statistical analyses were performed to evaluate the association of ERβ expression with clinical parameters, including prostate-specific antigen levels, radiotherapy, and estrogen exposure. Nuclear ERβ staining was detected in all bone CaP metastases (33 of 33) and nonosseous CaP metastases (27 of 27). However, a large variability in the percentage of immunoreactive cells (5% to 100%) was found among patients, as well as among individual patient samples. A statistically significant negative association between nuclear ERβ staining and estrogen exposure (P = 0.05) was detected. Our data have shown that ERβ is expressed in CaP metastases, validating the initiation of studies to evaluate selective ER modulators for treatment of advanced CaP.

UR - http://www.scopus.com/inward/record.url?scp=7444249518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444249518&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.05.036

DO - 10.1016/j.urology.2004.05.036

M3 - Article

VL - 64

SP - 814

EP - 820

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -